Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2003 May;14(5):1882–1899. doi: 10.1091/mbc.E02-10-0639

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2003, The American Society for Cell Biology

PMC Copyright notice

Figure 2. — Transient overexpression of EGFP-Rab5a wild-type and double-cysteine mutant proteins in HeLa cells. HeLa cells were transfected with EGFP-Rab5a (A–C), EGFP-Rab5aCGC (D–F), EGFP-Rab5aCCQNI (G–I), or with the respective constitutively active constructs, EGFP-Rab5aQ79L (J–L), EGFP-Rab5aQ79L, CGC (M–O) and EGFP-Rab5aQ79L, CCQNI (P–R). After 24 h, cells were permeabilized, fixed, and immunostained with an anti-TfR antibody (A–I) or with anti-EEA1 antibody (Panels J-R) as described under MATERIALS AND METHODS. The panels on the right show the merged fluorescent signals. Bar, 20 μm.

Figure 2. — Transient overexpression of EGFP-Rab5a wild-type and double-cysteine mutant proteins in HeLa cells. HeLa cells were transfected with EGFP-Rab5a (A–C), EGFP-Rab5aCGC (D–F), EGFP-Rab5aCCQNI (G–I), or with the respective constitutively active constructs, EGFP-Rab5aQ79L (J–L), EGFP-Rab5aQ79L, CGC (M–O) and EGFP-Rab5aQ79L, CCQNI (P–R). After 24 h, cells were permeabilized, fixed, and immunostained with an anti-TfR antibody (A–I) or with anti-EEA1 antibody (Panels J-R) as described under MATERIALS AND METHODS. The panels on the right show the merged fluorescent signals. Bar, 20 μm.